AzurRx (AZRX) Corporate Media Kit

15 . 15 • Covered up to September 2028, with Hatch-Waxman extension to September 2033 • FDA grants additional 12 years of exclusivity for novel biologics from first approval; EMA grants additional 10 years • No blocking patents identified to date • Potential to file additional IP for life cycle management MS1819 Intellectual Property